Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Dyslipidaemia

Revealing the effect of CETP inhibition in cardiovascular disease

Nature Reviews Cardiology volume 14, pages 635–636 (2017)Cite this article

Subjects

Initial randomized trials of cholesteryl ester transfer protein (CETP) inhibitors were terminated early owing to adverse effects or futility. The REVEAL trial now shows the benefit of CETP inhibition in coronary heart disease. Despite raising HDL-cholesterol levels, the cardiovascular effect of CETP inhibitors is probably due to lowering of non-HDL-cholesterol levels.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Non-HDL-cholesterol levels and risk of coronary heart disease in drug trials and genetic studies.

References

  1. Phillips, A. N. & Davey Smith, G. How independent are “independent” effects? Relative risk estimation when correlated exposures are measured imprecisely. J. Clin. Epidemiol. 44, 1223–1231 (1991).

    Article  CAS  Google Scholar 

  2. HPS3/TIMI55-REVEAL Collaborative Group. Effects of anacetrapib in patients with atherosclerotic vascular disease. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1706444 (2017).

  3. Holmes, M. V., Ala-Korpela, M. & Davey Smith, G. Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. Nat. Rev. Cardiol. 14, 577–590 (2017).

    Article  CAS  Google Scholar 

  4. White, J. et al. Association of lipid fractions with risks for coronary artery disease and diabetes. JAMA Cardiol. 1, 692–699 (2016).

    Article  Google Scholar 

  5. Webb, T. R. et al. Systematic evaluation of pleiotropy identifies 6 further loci associated with coronary artery disease. J. Am. Coll. Cardiol. 69, 823–836 (2017).

    Article  CAS  Google Scholar 

  6. Ference, B. A. et al. Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. JAMA 318, 947–956 (2017).

    Article  CAS  Google Scholar 

  7. Barter, P. J. et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109–2122 (2007).

    Article  CAS  Google Scholar 

  8. Schwartz, G. G. et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367, 2089–2099 (2012).

    Article  CAS  Google Scholar 

  9. Lincoff, A. M. et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N. Engl. J. Med. 376, 1933–1942 (2017).

    Article  Google Scholar 

  10. Burgess, S. & Davey Smith, G. Mendelian randomization implicates high-density lipoprotein cholesterol-associated mechanisms in etiology of age-related macular degeneration. Ophthalmology 124, 1165–1174 (2017).

    Article  Google Scholar 

Download references

Acknowledgements

M.V.H. works in a unit that receives funds from the University of Oxford and the UK Medical Research Council. G.D.S. works in a unit that receives funds from the University of Bristol and the UK Medical Research Council (MC_UU_12013/1). The funders had no role in study design, decision to publish, or preparation of the manuscript.

Author information

Authors and Affiliations

  1. Michael V. Holmes is at the Medical Research Council Population Health Research Unit, University of Oxford; the National Institute for Health Research Oxford Biomedical Research Centre, Oxford University Hospital, Old Road, Oxford OX3 7LE, UK; and the Medical Research Council Integrative Epidemiology Unit, University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK.,

    Michael V. Holmes

  2. Nuffield Department of Population Health, the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), University of Oxford, Roosevelt Drive, Oxford OX3 7LF, UK,

    Michael V. Holmes

  3. George Davey Smith is at the Medical Research Council Integrative Epidemiology Unit and the National Institute for Health Research Bristol Biomedical Research Centre, Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK; and the School of Social and Community Medicine, University of Bristol, Barley House, Oakfield Grove, Bristol BS8 2BN, UK.,

    George Davey Smith

  4. and the School of Social and Community Medicine, University of Bristol, Barley House, Oakfield Grove, Bristol BS8 2BN, UK.,

    George Davey Smith

Authors
  1. Michael V. Holmes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George Davey Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael V. Holmes.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Holmes, M., Smith, G. Revealing the effect of CETP inhibition in cardiovascular disease. Nat Rev Cardiol 14, 635–636 (2017). https://doi.org/10.1038/nrcardio.2017.156

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2017.156

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing